Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

MIRA Pharmaceuticals, Inc. - Common Stock (NQ:MIRA)

1.270 +0.050 (+4.10%)
Streaming Delayed Price Updated: 1:23 PM EDT, May 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 103,393
Open 1.250
Bid (Size) 1.260 (5)
Ask (Size) 1.280 (10)
Prev. Close 1.220
Today's Range 1.210 - 1.290
52wk Range 0.5100 - 5.010
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
MIRA Pharma Stock Soars To 2-Month High On $60M SKNY Deal: Retail Sentiment Strong
Retail sentiment on Stocktwits surged, with users expressing optimism about the merger’s success, despite a pullback in after-hours trading. 
Via Stocktwits
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga

Performance

YTD
+10.4%
+10.4%
1 Month
+23.3%
+23.3%
3 Month
+24.5%
+24.5%
6 Month
-3.1%
-3.1%
1 Year
+49.4%
+49.4%

More News

Read More
MIRA Pharmaceuticals Announces Board Approval of SKNY Acquisition Reflecting $60+ Million in Combined Enterprise Value Based on Independent Review
Via ACCESS Newswire
EXCLUSIVE: Mira Pharmaceuticals Board Approves SKNY Pharma Acquisition, Establishing Combined Enterprise Value Over $60 Million
Via Benzinga
MIRA Pharmaceuticals Reports No Brain Toxicity in FDA-Required Study of Ketamir-2, Confirming Absence of Ketamine-Linked Neurotoxicity
Via ACCESS Newswire
EXCLUSIVE: MIRA Pharmaceuticals Lead Program Ketamir-2 Shows No Brain Toxicity In FDA-Mandated Study
Via Benzinga
Exposures Product Safety
On Wednesday, there are stocks with unusual volume. Let's take a look.
Via Chartmill
MIRA Pharmaceuticals Reports Positive In Vitro Drug Release Data for Topical Ketamir-2, Targeting $11B+ U.S. Topical Pain Relief Market and Exploring FDA Fast Track Designation
Via ACCESS Newswire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Is Mira Pharmaceuticals Gaining or Losing Market Support?
Via Benzinga
Mira Pharma Leads Healthcare Buzz Surge On Promising Oral Ketamine Analog Preclinical Trial
Via Stocktwits
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Which stocks are gapping on Wednesday?
Via Chartmill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion
Via ACCESS Newswire
EXCLUSIVE: MIRA Pharmaceuticals Ketamir-2 Shows Efficacy In Diabetes-Associated Nerve Damage In Animal Study
Via Benzinga
MIRA Pharmaceuticals Enrolls First Subjects in Phase 1 Clinical Trial of Ketamir-2 for Neuropathic Pain
Via ACCESS Newswire
MIRA Pharmaceuticals Signs Binding Letter of Intent to Acquire SKNY Pharmaceuticals, Securing a $5 Million Capital Infusion to Advance Weight Loss and Smoking Cessation Drug Development
Via ACCESS Newswire
EXCLUSIVE: MIRA Pharmaceuticals Signs To Acquire SKNY Pharmaceuticals, Expand Pipeline Into Weight Loss And Smoking Cessation Drug
Via Benzinga
MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain
Via ACCESS Newswire
EXCLUSIVE: MIRA Pharmaceuticals Expands Pipeline, Enhances Value Proposition With Development Of Topical Formulation For Lead Pain Treatment Candidate
Via Benzinga
MIRA Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain
Via ACCESS Newswire
EXCLUSIVE: MIRA Pharmaceuticals Kick Starts Human Trial In Israel For Ketamir-2 For Neuropathic Pain
Via Benzinga
MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development
Via ACCESSWIRE
EXCLUSIVE: MIRA Pharmaceuticals Files FDA Application To Start Human Trials For Its Lead Pain Treatment
Via Benzinga
Exposures Product Safety

Frequently Asked Questions

Is MIRA Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, MIRA Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does MIRA Pharmaceuticals, Inc. - Common Stock trade on?
MIRA Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for MIRA Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for MIRA Pharmaceuticals, Inc. - Common Stock is MIRA on the Nasdaq Stock Market
What is the current price of MIRA Pharmaceuticals, Inc. - Common Stock?
The current price of MIRA Pharmaceuticals, Inc. - Common Stock is 1.270
When was MIRA Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of MIRA Pharmaceuticals, Inc. - Common Stock was at 05/27/25 01:23 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.